Emmaus Life Sciences Receives Marketing Authorization for Puerto Rico

TORRANCE, Calif., Feb. 2, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease (SCD) treatment, today announced that it has received marketing authorization from the Puerto Rico Department of Health for Endari® (L-glutamine oral powder). This approval marks a significant milestone in Emmaus' mission to improve the lives of people with SCD around the world and provides access to this important therapy for the patients living with SCD in Puerto Rico.  In addition, Endari® is approved in the United States, Israel, United Arab Emirates, Kuwait, Qatar, Bahrain, and Oman.

Read more at prnewswire.com